India moves closer to rolling out 'drugs for all' plan (Update)

July 6, 2012 by Penny MacRae

India is moving ahead with ambitious plans to spend nearly $5 billion to supply free drugs to patients -- bringing the nation closer to universal health coverage, officials said on Friday.

The "game-changing" scheme, in the words of one top Indian health ministry official, is part of the government's latest five-year spending programme (2012-17) and is expected to start in October.

The centre-left Congress government will pay 200 billion rupees or $3.61 billion while India's 29 states will be asked to kick in 66 billion rupees over the next five years to the scheme, a government statement said.

This initiative "would be a giant step in vastly expanding the access to medicines" in the country of 1.2 billion people, Ministry of Health joint secretary Arun Panda said.

The plan is set for formal approval next month but the drug scheme has already received its first chunk of 10 billion rupees from India's Planning Commission for 2012-13.

Prime Minister Manmohan Singh, a champion of the so-called "free-medicines-for-all" scheme", has also asked the health ministry to set up a central procurement agency to obtain the drugs in bulk.

"This starts us on the road to universal health care," K. Srinath Reddy, head of the Public Health Foundation of India, told AFP.

"It won't happen overnight -- it may be 10 or 15 years but we're on our way," said Reddy, who chaired a high-level government panel that laid out a roadmap for universal coverage.

The drugs plan could give a filip to the embattled Congress government, reeling from a string of corruption scandals and a sharply slowing economy, ahead of the general elections set for 2014.

Gainers will also be India's booming generic drug companies that include giants Ranbaxy, Dr Reddy's and Cipla.

The scheme will offer cheaper generic versions of branded drugs -- shutting out international pharmaceutical giants -- but the firms have normally looked to the burgeoning class of more affluent Indians to buy their medicines.

"Globally, governments traditionally get their drugs from generic sources so it's no surprise India is not turning to branded drugs," said an analyst at an Indian brokerage who could not be named due to his company's policy.

The 348 drugs to be provided include anesthetics, anti-AIDS, anti-psychotic, steroid, anti-ulcer, cholesterol-busting and cancer medicines. Some five percent of funds are being set aside to buy drugs off the essential list.

The government is seeking to "provide affordable healthcare to the poor and vulnerable," additional health secretary L.C. Goyal said, adding India aimed to launch "the game-changing programme from October."

Some 78 percent of spending on health comes from Indians' own pockets -- one of the highest rates globally. Also, some 72 percent of health spending goes on drugs and not treatment, said Public Health Foundation's Reddy.

The health ministry hopes by 2017, some 52 percent of Indians or some 600 million people will have access to the drug scheme.

"Universal health care is not possible without essential drugs and we thought this is one of the early and easily implementable steps," said Reddy.

"It's a very welcome commitment by the government," Leena Menghaney, a lawyer with humanitarian group Medecins sans Frontieres (Doctors Without Borders) told AFP.

"But supply management will be key to ensure the drugs do not end up in the private market," she said, as is often the case with subsidised goods in India.

Free medicines cannot alleviate the country's overburdened public health care system in which many hospitals lack up-to-date equipment and doctors. Wealthier Indians routinely opt for India's better resourced private hospitals.

But the government estimates 40 million Indians are forced into poverty annually because of treatment costs. Others are forced to seek loans or sell assets.

"When my brother got ill and was in hospital for weeks, we sold some land," said Raju Choudhary, a junior executive. "Anything like this could help people in such a situation."

Explore further: Indian drug giant Cipla slashes cancer drug prices

Related Stories

Indian drug giant Cipla slashes cancer drug prices

May 4, 2012
Indian drugs giant Cipla said Friday it has slashed by up to 76 percent prices of generic medicines used to treat brain, lung and kidney cancer in what the company called a "humanitarian move".

India firm shakes up cancer drug market with price cuts

June 17, 2012
Indian pharmaceutical tycoon Yusuf Hamied revolutionised AIDS treatment more than a decade ago by supplying cut-price drugs to the world's poor -- and now he wants to do the same for cancer.

Bayer challenges India cancer drug ruling

May 6, 2012
German pharmaceutical giant Bayer AG has challenged a ground-breaking Indian ruling that allowed a local firm to produce a vastly cheaper copy of its patented drug for kidney and liver cancer.

India probes charges of violations by drugs regulator

May 10, 2012
India's Health Ministry said Thursday it was examining charges that the government's top drug regulatory agency had colluded with pharmaceutical firms to approve drugs without proper clinical trials.

Indian expert panel to probe drugs regulator

May 11, 2012
India's Health Ministry said Friday it had set up an expert panel to review the operations of its drug regulatory agency, accused of colluding with pharmaceutical firms to approve drugs without trials.

Bayer mulls challenge to India cancer drug ruling

March 13, 2012
Bayer AG said Tuesday it was mulling ways to challenge a ground-breaking Indian ruling allowing a local firm to produce a vastly cheaper copy of a cancer drug made by the German pharmaceutical giant.

Recommended for you

Glucocorticoids offer long-term benefits for patients with Duchenne muscular dystrophy

November 22, 2017
Glucocorticoids, a class of steroid hormone medications often prescribed to patients with Duchenne muscular dystrophy (DMD), offer long-term benefits for this disease, including longer preservation of muscle strength and ...

Baby-boomers and millennials more afflicted by the opioid epidemic

November 21, 2017
Baby-boomers, those born between 1947 and 1964, experienced an excess risk of prescription opioid overdose death and heroin overdose death, according to latest research at Columbia University's Mailman School of Public Health. ...

Sensor-equipped pill raises technological, ethical questions

November 17, 2017
The first drug with a sensor embedded in a pill that alerts doctors when patients have taken their medications was approved by the Food and Drug Administration, raiding issues involving privacy, cost, and whether patients ...

New painkillers reduce overdose risk

November 16, 2017
Scientists on the Florida campus of The Scripps Research Institute (TSRI) have developed new opioid pain relievers that reduce pain on par with morphine but do not slow or stop breathing—the cause of opiate overdose.

Separating side effects could hold key for safer opioids

November 16, 2017
Opioid pain relievers can be extremely effective in relieving pain, but can carry a high risk of addiction and ultimately overdose when breathing is suppressed and stops. Scientists have discovered a way to separate these ...

US regulators approve first digital pill to track patients

November 14, 2017
U.S. regulators have approved the first drug with a sensor that alerts doctors when the medication has been taken, offering a new way of monitoring patients but also raising privacy concerns.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.